細胞番号 : 細胞名
RCB3534 : ED-40515(-)
update : 2024/01/17
|
| 細胞特性(Comment:英) | |
| 細胞特性(日) | |
| 細胞特性(寄託者記述:英) | ATL patient derived leukemic cell line (IL-2 independent). ED-40515, ED-40810, ED-41214, ED-50823, ED-70423C cell lines were established from the same patient's blood. |
| 細胞特性(寄託者記述:日) | |
| 使用条件(英) | 1) The material will be used for teaching or not-for profit research purpose only. To use the material for commercial purpose, he/she should refer to the establisher of the material. 2) The material will not be further distributed to others without the provider’s written consent. |
| 使用条件(日) | 1) 基礎的研究につきましては、使用制限はありません。商業利用の時には樹立者に事前にご相談ください。2) 第三者への分与は、樹立者の許可を得てください。 |
| 備考(英) | |
| 備考(日) | |
| 提供申込書類(英) |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
Cell line to be handled at BSL 2(C-0070.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
| 提供申込書類(日) |
依頼書C-0001.pdf
同意書(非営利学術目的)C-0003.pdf
同意書(営利目的)C-0003p.pdf
BSL2誓約書C-0069.pdf
|
|
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
|
| 提供手数料 |
手数料とお支払いについてはこちらをご覧ください。 |
|
細胞基本情報
|
|
寄託者 |
MAEDA, Michiyuki
|
| 樹立者 |
MAEDA, Michiyuki
|
| 寄託日 |
2011
|
| 動物種 |
_human
< Mammals
|
| 属名 |
Homo
|
| 種名 |
sapiens
|
| 人種 |
Japanese
|
| 採取組織 |
peripheral blood
|
| 病名 |
ATL
|
| 細胞分類 |
cancer
|
| 初代培養日 |
1984
|
|
細胞寿命 |
infinite
|
| 細胞形態 |
lymphocyte-like
|
| 特徴的生産物 |
HTLV-1 pro-virus DNA(+)
|
| 細胞表面抗原(寄託者) |
T cell marker (+), CD25 (+), HLA-DR (+)
|
| 造腫瘍性 |
Yes
|
| BSL |
BSL2
|
| Cellosaurus(Expasy) |
CVCL_JF70
|
|
細胞培養・検査情報
| |
寄託時情報 |
ロット情報 |
| 培地・試薬情報 |
培地・試薬一覧はこちらをご覧ください。 |
|
培養形態 |
Suspension cells
|
Suspension cells
|
| 培地 |
10%FCS, RPMI1640
|
RPMI1640 + 10% FBS
|
| 培養方法 |
|
浮遊細胞の培養に関する一般的な注意
|
| 抗生物質 |
100μg/ml kanamycin
|
Free
|
|
継代方法 |
|
dilution
|
|
播種細胞数 |
1-2 x 10 5 cells/ml
|
|
| 継代密度 |
1 : 5-10 split
|
1 : 10-20 split
|
| 継代・培地交換頻度 |
Subculture : 2 times/week
|
Subculture : 2 times/week
|
| 培養最適温度 |
37
℃
|
37
℃
|
| 二酸化炭素濃度 |
5
%
|
5
%
|
| 凍結培地 |
CELLBANKER
|
CELLBANKER 1
|
| 凍結方法 |
|
Slow freezing
|
| マイコプラズマ |
|
(-)
|
| 動物種PCR |
|
OK
|
| ウィルス（HIV) |
|
Undetected
|
| ウィルス（HTLV-1) |
|
DNA (+)
|
| ウィルス（EBV) |
|
(-)
|
| 飽和密度 |
5-10 x 10 5 cells/ml
|
|
| 個体識別検査 |
|
OK
|
|
寄託時情報
|
|
|
ロット情報
|
| D5S818 |
D13S317 |
D7S820 |
D16S539 |
vWA |
TH01 |
Amelogenin |
TPOX |
CSF1PO |
|
11,13
|
8,12
|
8,11
|
12
|
14,18
|
9
|
X,Y
|
8,11
|
10
|
|
| 文献情報 |
Reference(英) |
10件
|
| Reference(日) |
0件
|
| 利用者成果(英) |
0件
|
| 利用者成果(日) |
0件
|
| Reference(英) |
|
17268
Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, Ara T, Goto H, Izumiyama K, Otsuguro S, Perera LP, Hasegawa H, Maeda M, Hashino S, Maenaka K, Teshima T, Waldmann TA, Yang Y, Nakagawa M.
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas
Blood
2022
2022 Aug 3;blood.2022015646
PubMed ID: 35921533
DOI: 10.1182/blood.2022015646
|
|
3175
Michiyuki Maeda, Junko Tanabe-Shibuya, Paola Miyazato, Hiroshi Masutani, Jun-Ichirou Yasunaga, Kazumasa Usami, Akira Shimizu, Masao Matsuoka
IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia
Front Microbiol
2020
11:356
PubMed ID: 32210945
DOI: 10.3389/fmicb.2020.00356
|
|
2505
Ahsan MK, Masutani H, Yamaguchi Y, Kim YC, Nosaka K, Matsuoka M, Nishinaka Y, Maeda M, Yodoi J.
Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2
Oncogene
2006
25(15):2181-91
PubMed ID: 16314839
DOI: 10.1038/sj.onc.1209256
|
|
2502
Dewan MZ, Terashima K, Taruishi M, Hasegawa H, Ito M, Tanaka Y, Mori N, Sata T, Koyanagi Y, Maeda M, Kubuki Y, Okayama A, Fujii M, Yamamoto N.
Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/gammac(null) mice: suppression by an inhibitor against NF-kappaB
J Virol
2003
77(9):5286-94
PubMed ID: 12692230
DOI: 10.1128/jvi.77.9.5286-5294.2003
|
|
2507
Kawamata S, Sakaida H, Hori T, Maeda M, Uchiyama T.
The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines
Blood
1998
91(2):561-9
PubMed ID: 9427710
|
|
2509
Hiraiwa N, Dohi T, Kawakami-Kimura N, Yumen M, Ohmori K, Maeda M, Kannagi R.
Suppression of sialyl Lewis X expression and E-selectin-mediated cell adhesion in cultured human lymphoid cells by transfection of antisense cDNA of an alpha1-->3 fucosyltransferase (Fuc-T VII)
J Biol Chem
1996
271(49):31556-61
PubMed ID: 8940172
DOI: 10.1074/jbc.271.49.31556
|
|
2511
Ishii N, Asao H, Kimura Y, Takeshita T, Nakamura M, Tsuchiya S, Konno T, Maeda M, Uchiyama T, Sugamura K.
Impairment of ligand binding and growth signaling of mutant IL-2 receptor gamma-chains in patients with X-linked severe combined immunodeficiency
J Immunol
1994
153(3):1310-7
PubMed ID: 8027558
|
|
2506
Ohmori K, Takada A, Ohwaki I, Takahashi N, Furukawa Y, Maeda M, Kiso M, Hasegawa A, Kannagi M, Kannagi R.
A distinct type of sialyl Lewis X antigen defined by a novel monoclonal antibody is selectively expressed on helper memory T cells
Blood
1993
82(9):2797-805
PubMed ID: 7693048
|
|
2510
Maeda M, Noma T, Hama K, Honjo T.
Application of a human T cell line derived from a Sézary syndrome patient for human interleukin 4 assay
Immunol Lett
1988
18(4):247-53
PubMed ID: 3263317
DOI: 10.1016/0165-2478(88)90170-8
|
|
2501
Maeda M, Shimizu A, Ikuta K, Okamoto H, Kashihara M, Uchiyama T, Honjo T, Yodoi J.
Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia. Analysis of T cell receptor gene rearrangement
J Exp Med
1985
162(6):2169-74.
PubMed ID: 2866223
DOI: 10.1084/jem.162.6.2169
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト